# US 2019/0054183 A1 · Compositions and Methods for Targeted Delivery of Therapeutic and/or Diagnostic Agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0054183 A1
- Document ID: US20190054183A1
- Status: Published application
- Kind: A1
- Application number: 16/089,824
- Filed: 2017-04-13
- Published: 2019-02-21
- Earliest claimed: 2016-04-15
- Assignees: The Penn State Research Foundation
- Applicants: The Penn State Research Foundation
- Inventors: Jian YANG; Cheng DONG; Zhiwei XIE
- Web page: https://patentgrep.com/patent/US20190054183A1

## CPC

- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 47/593: {Polyesters, e.g. PLGA or polylactide-co-glycolide}
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61K 47/6937: {the polymer being PLGA, PLA or polyglycolic acid}
- A61K 49/0093: {Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In one aspect, methods of targeted nanoparticle and cell delivery are described herein. In some embodiments, methods described herein comprise coupling nanoparticles and cells to a carrier cell to form a nanoparticle-cell conjugate or cell-cell conjugate, disposing the nanoparticle-cell or cell-cell conjugate in a biological environment, and delivering the nanoparticles and cells to target cells or tissues located within the biological environment. The nanoparticles comprise a biodegradable photoluminescent polymer, and the nanoparticle-cell conjugate is formed using one or more click chemistry reaction products.

## Claims

### Claim at position 1

1-3. (canceled)

### Claim 4

A composition comprising a nanoparticle-cell conjugate, the nanoparticle-cell conjugate comprising:
a nanoparticle comprising a therapeutic agent and being conjugated to an enzyme-sensitive degradable peptide or to a pH sensitive degradable polymer; and
a carrier cell, wherein the nanoparticle is coupled to the carrier cell via a click chemistry reaction product between a first clickable moiety of the enzyme-sensitive degradable peptide or a first clickable moiety of the pH sensitive degradable polymer and a second clickable moiety on a surface of the carrier cell.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the nanoparticle is formed from a biodegradable photoluminescent polymer.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the biodegradable photoluminescent polymer is a block copolymer comprising:
a first block comprising a polymer or oligomer formed from the reaction product of (i) a polycarboxylic acid or a polycarboxylic acid equivalent, (ii) a polyol, and (iii) an amino acid; and
a second block comprising a polymer or oligomer that differs from the polymer or oligomer of the first block.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the polycarboxylic acid or polycarboxylic acid equivalent comprises citric acid, a citrate, or an ester of citric acid.

### Claim 8 (depends on 6)

The composition of claim 6, wherein the polyol comprises an α,ω-n-alkane diol, a poly(ethylene glycol), or a poly(propylene glycol).

### Claim at position 7

9-11. (canceled)

### Claim 12 (depends on 6)

The composition of claim 6, wherein the amino acid comprises an alkyl-substituted alpha-amino acid.

### Claim 13 (depends on 6)

The composition of claim 6, wherein the polymer or oligomer of the second block comprises a polylactone.

### Claim 14 (depends on 6)

The composition of claim 6, wherein the polymer or oligomer of the second block comprises poly-DL-lactide, poly-D-lactide, poly-L-lactide, a polyglycolide, a polycaprolactone, or a mixture or copolymer of one or more of the foregoing.

### Claim 15 (depends on 4)

The composition of claim 4, wherein the carrier cell is an immune cell.

### Claim 16 (depends on 4)

The composition of claim 4, wherein the carrier cell is a stem cell or white blood cell.

### Claim 17 (depends on 4)

The composition of claim 4, wherein the therapeutic agent comprises a targeted enzyme inhibitor.

### Claim 18

The composition of 17, wherein the targeted enzyme inhibitor comprises PLX4032.

### Claim 19 (depends on 4)

The composition of claim 4, wherein the therapeutic agent comprises a cytotoxic agent.

### Claim 20

(canceled)

### Claim 21 (depends on 4)

A method of targeted therapeutic agent delivery comprising:
disposing the composition of claim 4 into a biological environment; and
delivering the nanoparticles to target cells located within the biological environment.

### Claim 22 (depends on 21)

The method of claim 21, wherein, prior to disposing the composition into the biological environment, the carrier cell of the composition is isolated from human blood and functionalized with the second clickable moiety on the surface of the carrier cell.

### Claim 23 (depends on 21)

The method of claim 21, wherein the target cells are cancer cells.

### Claim 24 (depends on 21)

The method of claim 21, wherein the target cells form diseased, injured, or inflamed tissue.

### Claim 25 (depends on 24)

The method of claim 24, wherein the carrier cell of the composition is selected from the group consisting of a monocyte, a macrophage, a T cell, a B cell, and a red blood cell.

### Claim 26 (depends on 21)

The method of claim 21, wherein the biological environment is a blood stream or a blood vessel of a living organism.

### Claim 27 (depends on 21)

The method of claim 21, wherein the nanoparticle of the composition is formed from a biodegradable photoluminescent polymer and the method further comprises imaging the biological environment at one or more time points using photoluminescence emitted by the biodegradable photoluminescent polymer.

### Claim at position 24

28-76. (canceled)
